Takeshi Takahashi
Directeur/Membre du Conseil chez Pathalys Pharma, Inc.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Srini Akkaraju Akkaraju | M | 56 | 3 ans | |
Jay Shepard | M | 66 |
Pathalys Pharma, Inc.
Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | - |
Olivier Litzka | M | 56 | 2 ans | |
Neal Fowler | M | 62 |
Pathalys Pharma, Inc.
Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | - |
Jon Congleton | M | 60 | 4 ans | |
Krishnan Mahesh /davita/ | - | - |
Pathalys Pharma, Inc.
Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | - |
Derek DiRocco | M | 43 | 2 ans | |
Adam Levy | M | 46 | 2 ans | |
Ashwin Ram | M | - |
Pathalys Pharma, Inc.
Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | - |
BT Slingsby | M | 47 |
Pathalys Pharma, Inc.
Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | - |
David Rodman | M | 69 | 3 ans | |
Patrick Treanor | M | - |
Pathalys Pharma, Inc.
Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | 3 ans |
Jessica Ibbitson | F | - | 3 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Alexander G. Asam | M | 58 | 3 ans | |
Roger Zhang | M | - | - |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 15 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Takeshi Takahashi
- Réseau Personnel